Taro Pharmaceutical Industries Ltd.
Industry Group: Pharmaceuticals
Country/Region: Israel
Identifier: -
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 684 out of 850
Universe
Global Universe 12655 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Kiniksa Pharmaceuticals Ltd. |
29
Medium
|
441 out of 850 |
KPC Pharmaceuticals, Inc. |
33.3
High
|
626 out of 850 |
Sunflower Pharmaceutical Group Co., Ltd. |
34.1
High
|
664 out of 850 |
Taro Pharmaceutical Industries Ltd. |
34.9
High
|
684 out of 850 |
Harrow, Inc. |
37.2
High
|
768 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Taro Pharmaceutical Industries Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Taro Pharmaceutical Industries Ltd.'s Management of ESG Material Risk is Weak
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Taro Pharmaceutical Industries Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level